Natalizumab in progressive MS: Phase II results


A number of preliminary studies have investigated the possible effects of natalizumab in progressive MS. The latest is the open-label phase IIb NAPMS trial that examined the effect of treatment on osteopontin, an inflammatory marker, and CSF neurofilament (NfL) light chain, a marker of axonal damage  (Romme Christensen et al. Neurology 2014;82:1499-1507).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page